“…Polymorphism is very common amongst pharamaceutically important molecules and is responsible for differences in many properties (Bernstein, 2002(Bernstein, , 2011Nangia, 2008;Guranda & Deeva, 2010). The first monoclinic form (I) [space group P2 1 and z 0 = 1] of l-dopa HCl was reported in the 1970s (Jandacek & Earle, 1971;Mostad & Rømming, 1974). Herein, we report on the crystal and molecular structure of a second monoclinic polymorph, form (II) (space group I2) of l-dopa HCl.…”